Daniel D. Von Hoff

Daniel D. Von Hoff M.D., F.A.C.P.

TGen Physician-in-Chief & Distinguished Professor

TGen Executive Vice President and Director
Molecular Medicine Division

Sr. Consultant-Clinical Investigator

City of Hope

Professor of Medicine

Mayo Clinic, Clinical

Professor of Medicine
University of Arizona College of Medicine

Virginia G. Piper Distinguished Chair for Innovative Cancer Research
and Chief Scientific Officer
Honor Health Research Institute

Daniel D. Von Hoff M.D., F.A.C.P.

At TGen, Dr. Von Hoff is Physician-in-Chief, Distinguished Professor and Executive Vice President.  

Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many FDA approved agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegib, nab-paclitaxel, nal-IRI, and others. His clinical trial work has led to the approval of 3 of the 4 drugs approved by the FDA for treatment of patients with advanced pancreatic cancer. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies particularly for patients with advanced pancreatic cancer.

Dr. Von Hoff has published more than 675 papers, 140 book chapters and over 1170 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care.

Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in 2004-2010. Dr. Von Hoff is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX™ Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine approved by the FDA for patients with leukemia). Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and, past Editor-in-Chief of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Trial Cancer Research Workshop, which has graduated more than 2000 clinical trial physicians. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.

  • Mousses S, Kiefer J, Von Hoff D, Trent J., Using biointelligence to search the cancer genome: an epistemological perspective on knowledge recovery strategies to enable precision medical genomics Oncogene 27 2:S58-66. 2009
  • Von Hoff DD, Korn R, Mousses S., Pancreatic cancer--could it be that simple? A different context of vulnerability. Cancer Cell 7;16(1):7-8. 2009
  • Wang H, Han H, Mousses S, Von Hoff DD, Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents Semin Oncol Aug;33(4):513-20 2006
  • Colvin J, Monine MI, Faeder JR, Hlavacek WS, Von Hoff DD, Posner RG. , Simulation of large-scale rule-based models Bioinformatics 1;25(7) 910-917 2009
  • Ramanathan, RK, Abbruzzese J, Dragovich T, Kirkpatrick L, Guillen JM, Baker AF, Pestano LA, Green S and Von Hoff DD., A Randomized Phase II Study of PX-12, an inhibitor of Thioredoxin in Patients With Advanced Cancer of the Pancreas Following Progression after a Gemcitabine-Containing Combination. Can Chemo Pharmacol, Epub ahead of Print] 2010
  • Ruiz C, Lenkiewicz E, Evers L, Holley T, Robeson A, Kiefer J, Demeure MJ, Hollingsworth MA, Shen M, Prunkard D, Rabinovitch PS, Zellweger T, Mousses S, Trent J, Carpten J, Bubendorf L, Von Hoff DD, and Barrett MT., Advancing a Clinically Relevant Perspective of the Clonal Nature of Cancer. Proc. Natl. Acad. Sciences 108(29):12054-12059 2011
  • Henderson MC, Shaw YJ, Wang H, Han H, Hurley LH, Flynn G, Dorr RT, Von Hoff DD., UA62784, a novel inhibitor of centromere protein E kinesin-like protein Mol Cancer Ther Jan;8(1):36-44 2009
  • Wang H, Stephens B, Von Hoff DD, Han H. , Identification and characterization of a novel anticancer agent with selectivity against deleted in pancreatic cancer locus 4 (DPC4)-deficient pancreatic and colon cancer cells Pancreas Jul;38(5):551-7 2009
  • Trent J, S. L. Warner, S. Nwokenkwo, A. Sugeng, M. Barrett, B. J. Stephens, H. Han, and D. D. Von Hoff., Validation of TPX2 as a Potential Therapeutic Target in Pancreatic Cancer Cells. Clin, Cancer Res 15:6519-6528 2009
  • Stephens B, Han H, Hostetter G, Demeure MJ, Von Hoff DD., Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells Mol Cancer Ther Jan;7(1):202-10 2008
  • Baker AF, Koh MY, Williams RR, James B, Wang H, Tate WR, Gallegos A, Von Hoff DD, Han H, Powis G., Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer Pancreas, Mar;36(2):178-86 2008
  • Balagurunathan Y, Morse DL, Hostetter G, Shanmugam V, Stafford P, Shack S, Pearson J, Trissal M, Demeure MJ, Von Hoff DD, Hruby VJ, Gillies RJ, Han H., Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer Mol Cancer Ther. Sep;7(9):3071-80 2008
  • Warner SL, Muñoz RM, Bearss DJ, Grippo P, Han H, Von Hoff DD, Pdx-1-driven overexpression of aurora a kinase induces mild ductal dysplasia of pancreatic ducts near islets in transgenic mice Pancreas Oct;37(3):e39-44 2008
  • Chen S, Auletta T, Dovirak O, Hutter C, Kuntz K, El-Ftesi S, Kendall J, Han H, Von Hoff DD, Ashfaq R, Maitra A, Iacobuzio-Donahue CA, Hruban RH, Lucito R, Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification Cancer Biol Ther Nov 21;7(11) 2008
  • Zhu M, Gokhale VM, Szabo L, Munoz RM, Baek H, Bashyam S, Hurley LH, Von Hoff DD, Han H., Identification of a novel inhibitor of urokinase-type plasminogen activator Mol Cancer Ther Apr;6(4):1348-56 2007
  • Warner SL, Bashyam S, Vankayalapati H, Bearss DJ, Han H, Mahadevan D, Von Hoff DD, Hurley LH., Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach Mol Cancer Ther Jul;5(7):1764-73 2006
  • Han H, Von Hoff DD., Aurora sheds light on head and neck squamous cell carcinoma Clin Cancer Res Sep 1;12(17):5003-4 2006
  • Wang H, Han H, Von Hoff DD, Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells Cancer Res Oct 1;66(19):9722-30 2006
  • Warner SL, Munoz RM, Stafford P, Koller E, Hurley LH, Von Hoff DD, Han H, Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells Mol Cancer Ther Oct;5(10):2450-8 2006
  • Stephens BJ, Han H, Gokhale V, Von Hoff DD., PRL phosphatases as potential molecular targets in cancer Mol Cancer Ther Nov;4(11):1653-61 2005
  • J. P. Gray, Jr, D. J. Bearss, H. Han, R. Nagle, M. Tsao, N. Dean, and D. D. Von Hoff., Identification of Human Polo-like Kinase 1 as a Potential Therapeutic Target in Pancreatic Cancer. Mol Cancer Ther 3: 641-646. 2004
  • S. Rojanala, H. Han, R. M. Munoz, W. Browne, R. Nagle and D. D. Von Hoff, D. J. Bearss., The Mitotic Serine Threonine Kinase, Aurora-2, is a Potential Target for Drug Development in Human Pancreatic Cancer. Mol. Cancer Ther. 3, 451-457 2004
  • S. L. Warner, D. J. Bearss, H. Han, D. D. Von Hoff., Targeting aurora-2 kinase in cancer Mol. Cancer Ther 2, 589-595 2003
  • H. Han, D. J. Bearss and L. W. Browne, R. Calaluce, R. B. Nagle, D. D. Von Hoff. , Identification of Genes Differentially Expressed in Pancreatic Cancer Cells Using cDNA Microarray. Cancer Res 62, 2890-2896 2002
  • C. L. Grand, H. Han, R. M. Munoz, S. Weitman, D. D. Von Hoff, L. H. Hurley, and D. J. Bearss. , The Cationic Porphyrin TMPyP4 Downregulates c-MYC and hTERT Expression and Inhibits Tumor Growth in vivo. Mol. Cancer Ther 1, 565-573. 2002
  • Duan W, Rangan A, Vankayalapati H, Kim MY, Zeng Q, Sun D, Han H, Fedoroff OY, Nishioka D, Rha SY, Izbicka E, Von Hoff DD, Hurley LH. ,Design and synthesis of fluoroquinophenoxazines that interact with human telomeric G-quadruplexes and their biological effects Mol Cancer Ther Dec;1(2):103-20. 2001
  • Hurley LH, Wheelhouse RT, Sun D, Kerwin SM, Salazar M, Fedoroff OY, Han FX, Han H, Izbicka E, Von Hoff DD, G-quadruplexes as targets for drug design Pharmacol Ther Mar;85(3):141-58. 2000
  • Ramesh, A., Trevino, R., von Hoff, D., Kim, S, Clustering Context-Specific Gene Regulatory Networks. Pacific Symposium on Biocomputing, Jan 5-9, 2010, Big Island, Hawaii, US. 2010
  • Stephan EA, Chung TH, Grant CS, Kim S, Von Hoff DD, Trent JM, Demeure MJ. , Adrenocortical carcinoma survival rates correlated to genomic copy number variants Mol Cancer Ther 7(2):425-31 2008
  • Weiss GJ and Von Hoff DD.. , Hunting the Hedgehog Pathway Clin Pharmacol Ther Jun;87(6):743-7. 2010
  • Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad M,J, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC, de Sauvage FJ, Low JA., Inhibition of the Hedgehog Pathway in Advanced Basal Cell Carcinoma. N Engl J Med 17;361(12):1164-72. 2009
  • Demeure MJ, Sielaff T, Koep L, Prinz R, Moser AJ, Zeh H, Hostetter G, Black J, Decker A, Rosewell R, Bussey K, Von Hoff, DD., Multi-institutional tumor banking: lessons learned from a pancreatic cancer biospecimens repository Pancreas 39(7): 949-954 2010
  • Lorenzi PL, Reinhold WC, Rudelius M, Gunsior M, Shankavaram U, Bussey KJ, Scherf U, Eichler GS, Martin SE, Chin K, Gray JW, Kohn EC, Horak ID, Von Hoff DD, Raffeld M, Goldsmith PK, Caplen NJ, Weinstein JN., Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Molecular Cancer Therapeutics 5(11):2613-23 2006
  • Schwartz DL, Bankson JA, Lemos R Jr, Lai SY, Thittai AK, He Y, Hostetter G, Demeure MJ, Von Hoff DD, Powis G., Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther 9(7):2057-67 2010
  • Xie L, Kassner M, Munoz RM, Que Q, Kiefer J, Zhao Y, Mousses S, Yin H, Von Hoff DD, and Han H. , Kinome-widesiRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors. Biochem Pharmacol Feb 15;83(4):452-61 PMCID: PMC3265162. 2012
  • Harradine KA, Kassner M, Chow D, Aziz M, Von Hoff DD, Baker J, Yin H, Pelham RJ., Functional genomics reveals diverse cellular processes that modulate tumor cell response to oxalipatin. Mol Cancer Res Epub online 2010
  • Azorsa, D.O., Gonzales I.M., Basu, G.D., Choudhary, A., Arora, S., Bisanz, K.M., Kiefer, J.A., Henderson, M.C., Trent, J.M., Von Hoff, D.D., and Mousses, S., Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Trans Med 7:43 2009
Back To Top